Hal Barron (Endpoints News)
March 11, 2021 06:58 AM ESTUpdated March 12, 01:29 PM
R&D
Coronavirus

Glax­o­SmithK­line, Vir gear up for EUA, cit­ing ear­ly PhI­II Covid-19 win with 'best-in-class' an­ti­body con­tender

Amber Tong

Glax­o­SmithK­line’s big bet on Vir Biotech­nol­o­gy and its an­ti­body tech­nol­o­gy has paid off.

The part­ners say they are now ready to ap­ply for an emer­gency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times